retatrutide trial phase Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal 3 obesity Today, we shared new data

The loss of food as a coping mechanism This is the factor that most medical discussions completely ignore

however, their use is limited due to the development of intolerable anticholinergic adverse events, including confusion, drowsiness, memory impairment, dry mouth, constipation, and visual changes

Observational studies have suggested that weight reduction can improve lymphedema symptoms and reduce limb volume in obese patients with the condition, though the quality of evidence remains limited

Novel pharmacological targets The neurokinin-1 receptor antagonist tradipitant was reported to improve nausea in gastroparesis, but the study was underpowered to show a benefit in the subgroup with diabetes [77]

Do nothing else differently